The core activity of Histide AG is the development and marketing of biotechnological products, in particular so-called Cell Recoding Molecules (CRM), which are intended for the treatment of rare diseases and tissue regeneration. The company focuses on the research and development of non-mutagenic extracellular therapeutic agents and has a strong patent and technology platform.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentMedical Technology Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Platform based on Cell Recoding Molecules™ and Cell Recoding Peptides™ for extracellular, non-mutagenic therapeutic approaches; designed for different cell types, indications and application formats.
Research and Development of Recoding Therapeutics™
Research, development and new applications for CRM™ in collaboration with academic partners; focus on cell biology, mechanisms of action and formulation development.
Patent and IP Management
Patent applications, drafting, prosecution, assessment, litigation and IP strategy for the CRM™ technology, as well as protection of the technology and application portfolio.
Out-licensing and Partnership Development
Partnerships and out-licensing of the technology for pharmaceutical and other application areas; business development for collaboration with strong partners.
Comparisons
HISTIDE AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank HISTIDE AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once HISTIDE AG has claimed this profile, we'll publish editorial articles and case studies here together.